Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 241-620-3 | CAS number: 17636-10-1
Specific investigations: other studies
Administrative data
Link to relevant study record(s)
Description of key information
MPS possesses uroprotective efficacy against ifosfamide induced haemorrhagic cystitis in rats at dose levels of 100 and 215 mg/kg bw.
Additional information
Sodium-3-mercapto-propane sulfonate (Asta 7100 = MPS) was tested for its uroprotective efficacy in 5 Sprague Dawley rats treated with 68 mg/kg ifosfamide that is known to induce haemorrhagic cystitis (Brock et al., 1981). MPS was administered by i. v. administration 15 min before the injection of ifosfamide at the screening dose of 100 mg/kg bw and thereafter was raised or lowered in steps with a factor of 2.15. The dose levels were 21.5, 68.1 and 215 mg/kg bw. The uroprotective efficacy of MPS was evaluated 24 hours after the administration of ifosfamide. The rats were killed and the urinary bladders were evaluated (inflammation, bleeding and weight). The severity of the inflammation of the bladder after i.v. administration of ifosfamide was dose-dependent. An ifosfamide dose of 68 mg/kg always induced an approximately 2- fold increase in the wet weight of the bladder and a damage score of about 2. Some of the rats also showed bladder haemorrhages. The scoring system used takes into account two parameters: firstly, increased capillary permeability (which is demonstrable objectively by the extravasal occurrence of intravenously injected trypan blue) and secondly, the increase in the weight of the bladder, which can also be assessed macroscopically as a swelling of the bladder. In some selected groups the bladder damage and the extent of bladder protection were also investigated histologically. The uroprotective effect of MPS was dose-dependent. It was reflected in a reduced increase in the bladder weight and reduced extravasation of trypan blue, and it was also demonstrable histologically. MPS exerted its uroprotective effect at doses of 100 and 215 mg/kg bw. MPS was, however, less effective than its short-chain homologue mesna (CAS 19767 -45 -4).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
